November 19 2013 Issue

1) Fibroblast growth factor-21 being a sensitive biomarker of mitochondrial disease and 2) Topic of the month: Area of functional symptoms and conversion disorder. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. James Addington interviews Dr. Carolyn Sue about her paper on fibroblast growth factor-21 being a sensitive biomarker of mitochondrial disease. Dr. Roy Strowd is reading our e-Pearl of the week about MAD for seizures. In the next part of the podcast Dr. Shanna Patterson interviews Dr. Jon Stone about functional neurologic symptoms and how to discuss this diagnosis with patients. The participants had nothing to disclose except Drs. Sue, Strowd and Stone.Dr. Sue receives research support from the National Health and Medical Research Council of Australia.Dr. Strowd serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Stone receives speaker honoraria from the Movement Disorders Society, Norwegian Neuropsychiatric Association, British Medical Association, Royal College of Psychiatrists, UCB, Tribunals Judiciary (UK) and St Louis Dept of Neurology; does expert witness work and runs a free patient information website.